Syndax Pharmaceuticals (SNDX) Shares Drop 15% After Phase 2 Trial Miss in IPF

gurufocus.com · 2026-10-12

On October 12, 2026, Syndax Pharmaceuticals Inc (NASDAQ: SNDX) saw its shares decline roughly 15% in after-hours trading following the announcement that its idi

TickrTrends take: Incyte Corporation operates in the Healthcare sector where clinical trial outcomes significantly influence investor sentiment and valuation multiples. While this headline concerns a competitor in the respiratory/IPF space, setbacks in phase trials across the healthcare industry can create broader pressure on valuations and investor confidence in similar therapeutic areas. Given TickrTrends' current assessment of INCY as undervalued, observers should monitor whether INCY's pipeline programs face similar clinical headwinds or whether market weakness in healthcare provides a valuation opportunity.

Read the full story at gurufocus.com →